甲基乙二醛 (Methylglyoxal, MG)，為糖基化終產物 (Advanced glycation end product, AGEs) 的前驅物，會在中樞神經系統中引起神經元功能障礙，其累積與多種疾病相關，例如：糖尿病及神經退化性疾病。阿茲海默症 (Alzheimer’s disease, AD) 為最常見的神經退化性疾病，主要症狀為影響患者的記憶、思維、甚至是維持日常生活的能力，而老年斑塊積累以及神經原纖維纏結為典型的病理特徵。維生素E為生育三烯醇 (Tocotrienol, T3) 及生育醇 (Tocopherol, T) 之統稱。具有抗氧化、抗老化、抗炎及神經保護等多種生理活性。文獻指出，生育三烯醇之抗氧化及抗炎等生理活性優於生育醇。本實驗選用δ-生育三烯醇作為實驗樣品，探討其在小鼠腦內對於甲基乙二醛所誘導神經損傷之保護效果，評估δ-生育三烯醇是否具有保護腦神經之潛力。實驗結果顯示，餵食δ-T3對小鼠之體重及攝食量並無顯著性影響。水迷宮試驗結果顯示，餵食δ-T3後，與負控組相比，小鼠之空間記憶學習能力有回復之趨勢。而以western blot結果顯示，餵食δ-T3後，與負控組相比，PI3K、p-Akt、p-GSK-3β及BDNF之蛋白表現量提升，且p-Tau、Aβ1-42及cleaved-caspase 3之蛋白表現量下降。總結以上結果，δ-T3具有保護MG誘導小鼠腦神經損傷之功效。

Methylglyoxal (MG), a precursor of glycation end products (advanced glycation end product, AGEs), induces various stress responses in the central nervous system and causes neuronal dysfunction, and is associated with a variety of diseases, such as diabetes and neurodegenerative diseases. Alzheimer's disease (AD) is the most common neurodegenerative disease. The main symptoms are affecting the patient's memory, thinking, and even the ability to maintain daily life. Age-related plaque accumulation and neurofibrillary tangles are important typical features of Alzheimer’s disease. Vitamin E is a collective name for tocotrienol (T3) and tocopherol (T). It has many physiological activities such as anti-oxidation, anti-aging, anti-inflammatory and neuroprotection. The literature indicates that the physiological activity of T3 is better than tocopherol. In this experiment, δ-T3 was selected as an experimental sample to investigate its protective effect on nerve damage induced by methylglyoxal in mice, and to evaluate whether δ-T3 has the potential for protection of cranial nerve. The experimental results showed that the feeding of δ-tocotrienol had no significant effect on the body weight and food intake of the mice. The water maze test results showed that after feeding δ-tocotrienol, the spatial memory learning ability of mice was reverted compared with the negative control group. Western blot analysis showed that after feeding δ-T3, the protein expression of PI3K, p-Akt, p-GSK-3β and BDNF was increased compared with the negative control group, and the protein expression of p-Tau, Aβ1-42 and cleaved-caspase3 was decreased. Summarize the above results, δ-T3 has the protective effects on brain damage induced by MG in mice.

陳原。2015。糖尿病性丙酮醛致痛機制及其清除劑鎮痛作用的研究。上海交通大學藥學院。碩士論文。
Acheson A., Conover J. C., Fandl J. P., DeChiara T. M., Russell M., Thadani A., Squinto S. P., Yancopoulos G. D., Lindsay R. M. 1995. A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature 374: 450-453.
Adachi H and Ishii N. 2000. Effects of tocotrienols on life span and protein carbonylation in Caenorhabditis elegans. Journals of Gerontology Series A: Biological sciences and medical sciences 55: 280-285.
Affoo R. H., Foley N., Rosenbek J., Kevin Shoemake J., Martin R. E. 2013. Swallowing dysfunction and autonomic nervous system dysfunction in Alzheimer’s disease: a scoping review of the evidence. Journal of the American geriatrics society 61: 2203-2213.
Ahmed N., Ahmed U., Thornalley P. J. 2005. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer’s disease and link to cognitive impairment. Journal of neurochemistry 92: 255-263
Ahsan H, Ahad A., Iqbal J., Siddiqui W. A. 2014. Pharmacological potential of tocotrienols: a review. Nutrition & Metabolism 11: 1-22.
Alvarez-Suarez J. M., Gasparrini M., Forbes-Hernández T. Y., Mazzoni L., & Giampieri F. 2014. The Composition and Biological Activity of Honey: A Focus on Manuka Honey. Foods (Basel, Switzerland) 3: 420-432.
Angeloni C., ZamboninL., Hrelia S. 2014. Role of methylglyoxal in Alzheimer's disease. BioMed research international 238485. doi:10.1155/2014/238485.
Bader Lange M. L., St Clair D., Markesbery W. R., Studzinski C. M., Murphy M. P., Butterfield D. A. 2010. Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Bader Lange, Miranda L et al. “Age-related loss of phospholipid asymmetry in APP (NLh) /APP (NLh) x PS-1(P264L) / PS-1 (P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiology of disease 38: 104-115.
Beeri M. S., Moshier E., Schmeidler J. 2011. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mechanisms of ageing and development 132: 583-587.
Beeri M. S., Moshier E., Schmeidler J., Godbold J., Uribarri J., Reddy S., Sano M., Grossman H. T., Cai W., Vlassara H., Silverman J. M. 2011. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mechanisms of ageing and development 132: 583-587.
Bielska A. A and Zondlo N. J. 2006. Hyperphosphorylation of tau induces local polyproline II helix. Biochemistry 45: 5527-5537.
Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
Chen Y. J., Huang X. B., Li Z. X., Yin L. L., Chen W. Q., Li L. 2010. Tenuigenin protects cultured hippocampal neurons against methylglyoxal-induced neurotoxicity. European journal of pharmacology 645: 1-8.
Conte C., Floridi A., Aisa C., Piroddi M., Floridi A., Galli F. 2004. Gamma-tocotrienol metabolism and antiproliferative effect in prostate cancer cells. Annals of the New York Academy of sciences 1031: 391-394.
Desai K., Wu L. 2007. Methylglyoxal and advanced glycation endproducts: New therapeutic horizons? Recent patents on cardiovascular drug discovery 2: 89-99.
Du Y., Wu H. T., Qin X. Y., Cao C., Liu Y., Cao Z. Z., Cheng Y. 2018. Postmortem brain, cerebrospinal fluid, and blood neurotrophic factor levels in. Alzheimer’s disease 65: 289-300.
Durani L. W., Hamezah H. S., Ibrahim N. F., Yanagisawa D., Nasaruddin M. L., Mori M., Azizan K. A., Damanhuri H. A., Makpol S., Wan N. W. Z., Tooyama I. 2018. Tocotrienol-Rich Fraction of Palm Oil Improves Behavioral Impairments and Regulates Metabolic Pathways in AβPP/PS1 Mice. Journal of Alzheimer’s disease 64: 249-267.
Edaravone protects against methylglyoxal-induced barrier damage in human brain endothelial cells. PloS one 9, e100152, Published July 17, 2014, from the NCBI web: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102474/.
Embi N., Rylatt D. B., Cohen P. 1980. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. European journal of biochemistry 107: 519-527.
Engel T., Hernandez F., Avila J., Lucas J. J. 2006. Full reversal of Alzheimer’s disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. Journal of neuroscience 26: 5083-5090.
Fawver J. N., Schall H. E., Petrofes Chapa R. D., Zhu X., Murray I. V. 2012. Amyloid-beta metabolite sensing: biochemical linking of glycation modification and misfolding. Journal of Alzheimer’s disease 30: 63-73.
Gillette-Guyonnet S., Secher M., Vellas B. 2013. Nutrition and neurodegeneration: epidemiological evidence and challenges for future research. British journal of clinical pharmacology 75: 738-755.
Glenner G. G and Wong C. W. 1984. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochemical and biophysical research communications 122: 1131-1135.
Goh S. H., Hew N. F., Norhanom A. W., Yadav M. 1994. Inhibition of tumour promotion by various palm-oil tocotrienols. International journal of cancer 57: 529-531.
Grundke-Iqbal I., Iqbal K., Tung Y. C., Quinlan M., Wisniewski H. M., Binder L. I. 1986. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proceedings of the national academy of sciences 83: 4913-4917.
Guthrie N., Gapor A., Chambers A. F., Carroll K. K. 1997. Palm oil tocotrienols and plant flavonoids act synergistically with each other and with Tamoxifen in inhibiting proliferation and growth of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells in culture. Asia pacific journal of clinical nutrition 6: 41-45.
Hake A. M. 2001. Use of cholinesterase inhibitors for treatment of Alzheimer disease. Cleveland clinic journal of medicine 68: 608-609, 613-614, 616.
He L., Mo H., Hadisusilo S., Qureshi A. A., Elson C. E. 1997. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. Journal of nutrition 127: 668-674.
Heimfarth L., Loureiro S. O., Pierozan P. 2013. Methylglyoxal-induced cytotoxicity in neonatal rat brain: a role for oxidative stress and MAP kinases. Metabolic of brain disease 28: 429-438.
Honek J. F. 2015. Glyoxalase biochemistry. Biomolecular Concepts 6: 401-414.
Hoover B. R., Reed M. N., Su J., Penrod R. D., Kotilinek L. A., Grant M. K., Pitstick R., Carlson G. A., Lanier L. M., Yuan L. L., Ashe K. H., Liao D. 2010. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68:1067-1081.
Hoshi M., Takashima A., Noguchi K., Murayama M., Sato M., Kondo S., Saitoh Y., Ishiguro K., Hoshino T., Imahori K. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proceedings of the National Academy of science of the United States of America 93: 2719-2723.
Huang E. J and Reichardt L. F. 2003. Trk receptors: roles in neuronal signal transduction. Annual review of biochemistry 72: 609-642.
Huang E. J., Reichardt L. F. 2001. Neurotrophins: roles in neuronal development and function. Annual Review of Neuroscience 24: 677-736.
Iqbal K., Alonso Adel C., Chen S., Chohan M. O., El-Akkad E., Gong C. X., Khatoon S., Li B., Liu F., Rahman A., Tanimukai H., Grundke-Iqbal I. 2005. Tau pathology in Alzheimer disease and other tauopathies. Biochimica et biophysica acta 1739: 198-210.
Jiang Q., Christen S., Shigenaga M. K., Ames B.N.2001. gamma-Tocopherol, the major form of vitamin E in the US diet, deserves more attention. American journal of clinical nutrition 74: 714-722.
Kalapos M. P. 1999. Methylglyoxal in living organisms: chemistry, biochemistry, toxicology and biological implications. Toxicology letters 110: 145-175.
Kamat J. P and Devasagayam T. P. 1995. Tocotrienols from palm oil as potent inhibitors of lipid peroxidation and protein oxidation in rat brain mitochondria. Neuroscience letters 195: 179-182.
Kamat J. P., Sarma H. D., Devasagayam T. P., Nesaretnam K., Basiron Y. 1997. Tocotrienols from palm oil as effective inhibitors of protein oxidation and lipid peroxidation in rat liver microsomes. Molecular and cellular biochemistry 170: 131-137.
Kaur S., Zilmer K., Leping V., Zilmer M. 2013. Serum methylglyoxal level and its association with oxidative stress and disease severity in patients with psoriasis. Archives of dermatological research 305: 489-494.
Kettunen P., Larsson S., Holmgren S., Olsson S., Minthon L., Zetterberg H., Blennow K., Nilsson S., Sjölander A. 2015. Genetic variants of GSK-3β are associated with biomarkers for Alzheimer’s disease and cognitive function. Journal of Alzheimer’s disease 44: 1313-1322.
Khor H. T, Ng T. T. 2000. Effects of administration of alpha-tocopherol and tocotrienols on serum lipids and liver HMG CoA reductase activity. Food science and nutrition 51: 3-11.
Kiris E., Ventimiglia D., Feinstein S. C. 2010. Quantitative analysis of MAP-mediated regulation of microtubule dynamic instability in vitro focus on Tau. Methods in cell biology 95: 481-503.
Kitagishi Y., Nakanishi A., Ogura Y., Matsuda S. 2014. Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer's disease. Alzheimer’s research & therapy 6: 35.
Koike S., Kayama T., Yamamoto S., Komine D., Tanaka R., Nishimoto S., Suzuki T., Kishida A., Ogasawar Y. 2016. Polysulfides protect SH-SY5Y cells from methylglyoxal-induced toxicity by suppressing protein carbonylation: A possible physiological scavenger for carbonyl stress in the brain. NeuroToxicology 55: 13-19.
Kuhla B., Luth H. J., Haferburg D., Boeck K., Arendt T., Munch G. 2005. Methylglyoxal, glyoxal, and their detoxification in Alzheimer’s disease. Annals of the New York Academy of sciences 1043: 211-216.
Larsson E., Nanobashvili A., Kokaia Z., Lindvall O. 1999. Evidence for neuroprotective effects of endogenous brain-derived neurotrophic factor after global forebrain ischemia in rats. Journal of cerebral blood flow and metabolism: official journal of the international society of cerebral blood flow and metabolism 19: 1220-1228.
Lee B. H., Hsu W. H., Chang Y. Y., Kuo H. F., Hsu Y. W., Pan T. M. 2012. Ankaflavin: a natural novel PPARγ agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo. Free radical biology and medicine 53: 2008-2016.
Li W., Maloney R. E., Circu M. L., Alexander J. S., Aw T. Y. 2012. Acute carbonyl stress induces occludin glycation and brain microvascular endothelial barrier dysfunction: role for glutathione-dependent metabolism of methylglyoxal. Free radical biology & medicine 54: 51-61.
Li X. H., Lv B. L., Xie J. Z., Liu J., Zhou X. W., & Wang J. Z. 2012. AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiology of aging 33: 1400-1410.
Liu J., Wang R., Desai K., Wu L. 2011. Upregulation of aldolase B and overproduction of methylglyoxal in vascular tissues from rats with metabolic syndrome. Cardiovasc research 92: 494-503.
Llorens-Martín M., Jurado J., Hernández F., Avila J. 2014. GSK-3β, a pivotal kinase in Alzheimer disease. Frontiers in molecular neuroscience 7: 46, Published May 21, 2014, from the NCBI web: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033045/#B39.
Lopes da Silva S., Vellas B., Elemans S., Luchsinger J., Kamphuis P., Yaffe K., Sijben J., Groenendijk M., Stijnen T. 2013. Plasma nbibuutrient status of patients with Alzheimer’s disease: systematic review and meta-analysis. Alzheimers dement 10: 485-502.
Lucas J. J., Hernández F., Gómez-Ramos P., Morán M. A., Hen R., Avila J. 2001. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. The EMBO journal 20: 27-39.
Lundkvist J., Halldin M. M., Sandin J., Nordvall G., Forsell P., Svensson S., Jansson L., Johansson G., Winblad B., Ekstrand J. 2014. The battle of Alzheimer’s Disease – the beginning of the future Unleashing the potential of academic discoveries. Pharmacology 5:1-6.
Markesbery W. R. 1997. Oxidative stress hypothesis in Alzheimer’s disease. Free radical biology and medicine 23: 134-147.
Mattson M. P., Duan W., Wan R., Guo Z. 2004. Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. The journal of the American society for experimental neurotherapeutics 1: 111-116.
McGowan E., Pickford F., Kim J., Onstead L., Eriksen J., Yu C., Skipper L., Murphy M. P., Beard J., Das P., Jansen K., DeLucia M., Lin W. L., Dolios G., Wang R., Eckman C. B., Dickson D. W., Hutton M., Hardy J., Golde T. 2005. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47: 191-199.
Mishima K., Tanaka T., Pu F., Egashira N., Iwasaki K, Hidaka Ryoji., Matsunaga K., Takata J., Karube Y., Fujiwara M. 2003. Vitamin E isoforms α-tocotrienol and γ-tocopherol prevent cerebral infarction in mice. Neuroscience letters 337: 56-60.
Nakaso K., Nakamura C., Sato H., Imamura K., Takeshima T., Nakashima K. 2006. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochemical and Biophysical Research Communications 339: 915-922.
Nakaso K., Tajima N., Horikosh Y., Nakasone M., Hanaki T., Kamizaki K., Matsura T. 2014. The estrogen receptor β-PI3K/Akt pathway mediates the cytoprotective effects of tocotrienol in a cellular Parkinson's disease model. Biochimica et Biophysica Acta (BBA) - Molecular basis of disease 1842: 1303-1312.
Nesaretnam K., Stephen R., Dils R., Darbre P. 1998. Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids 33: 461-469.
Ng L. T., Leong W. H., Ho D. 2002. The pharmacological properties of palm tocotrienols. Chinese pharmaceutical journal 54: 63-75.
Nigro C., Raciti G. A., Leone A., Fleming T. H., Longo M., Prevenzano I., Fiory F., Mirra P., D’Esposito V., Ulianich L., Nawroth P. P., Formisano P., Beguinot F., Miele C. 2014. Methylglyoxal impairs endothelial insulin sensitivity both in vitro and in vivo. Diabetologia 57: 1485-1494.
O'Byrne D., Grundy S., Packer L., Devaraj S., Baldenius K., Hoppe P. P., Kraemer K., Jialal I., Traber M. G. 2000. Studies of LDL oxidation following alpha-, gamma-, or delta-tocotrienyl acetate supplementation of hypercholesterolemic humans. Free radical biology and medicine 29: 834-845.
Okouchi M., Okayama N., Aw T. Y. 2009. Preservation of cellular glutathione status and mitochondrial membrane potential by N-acetylcysteine and insulin sensitizers prevent carbonyl stress-induced human brain endothelial cell apoptosis. Current neurovascular research 6: 267-278.
Osakada F., Hashino A., Kume T., Katsuki H., Kaneko S., Akaike A. 2004. Alpha-tocotrienol provides the most potent neuroprotection among vitamin E analogs on cultured striatal neurons. Neuropharmacology 47: 904-915.
Paglini G., Peris L., Mascotti F., Quiroga S., Caceres A. 2000. Tau protein function in axonal formation. Neurochemical research 25: 37-42.
Parihar M. S., Hemnani T. 2004. Alzheimer's disease pathogenesis and therapeutic interventions. Journal of clinical neuroscience 11: 456-467.
Parker R. A., Pearce B. C., Clark R. W., Gordan D. A., Wright J. J. 1993. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. The journal of biological chemistry 268: 11230-11238.
Pearce B. C., Parker R.A., Deason M. E., Qureshi A. A., Wright J. J. 1992. Hypocholesterolemic activity of synthetic and natural tocotrienols. Journal of medical chemistry 35: 3595-3606.
Peh H. Y., Tan W. S. D., Liao W., Wong W. S. F. 2016. Vitamin E therapy beyond cancer: Tocopherol versus tocotrienol. Pharmacology & therapeutics 162: 152-169.
Petersen R. C., Smith G. E., Waring S. C., Ivnik R. J., Tangalos E. G., Kokmen E. 1999. Mild cognitive impairment: clinical characterization and outcome. Archives of neurology 56: 303-308.
Qi L., Chen Z., Wang Y., Liu X., Liu X., Ke L., Zheng Z., Lin X., Zhou Y., Wu L., Liu L. 2017. Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β. American journal of translational research 9: 247-260.
Qi L., Ke L., Liu X., Liao L., Ke S., Liu X., Wang Y., Lin X., Zhou Y., Wu L., Chen Z., Liu L. 2016. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model. European journal of pharmacology 783: 23-32.
Qureshi A. A., Bradlow B. A., Brace L., Manganello J., Peterson D. M., Pearce B. C., Wright J. J., Gapor A., Elson C. E. 1995. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids 30: 1171-1177.
Qureshi A. A., Qureshi N., Hasler-Rapacz J. O., Weber F. E., Chaudhary V., Crenshaw T. D., Gapor A., Ong A. S., Chong Y. H., Peterson D. 1991. Dietary tocotrienols reduce concentrations of plasma cholesterol, apolipoprotein B, thromboxane B2, and platelet factor 4 in pigs with inherited hyperlipidemias. The American journal of clinical nutrition 53: 1042-1046.
Ramasamy R., Vannucci S. J., Yan S. S., Herold K., Yan S. F., Schmidt A. M. 2005. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15: 16-28.
Sen C. K., Khanna S., Roy S. 2004. Tocotrienol: the natural vitamin E to defend the nervous system?. Annals of the New York academy of sciences 1031: 127-142.
Serbinova E., Kagan V., Han D., Packer L. 1991. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free radical biology and medicine 10: 263-275.
Silva M. S., Gomes R. A., Ferreira A. E., Freire A. P., Cordeiro C. 2013. The glyoxalase pathway: the first hundred years and beyond. The biochemical journal 453: 1-15.
Solfrizzi V., Panza F. 2014. Mediterranean diet and cognitive decline. A lesson from the whole-diet approach: what challenges lie ahead?. Journal of Alzheimer’s disease 39: 283-286.
Spittaels K., Van D. H. C., Van D. J., Geerts H., Mercken M., Bruynseels K., Lasrado R., Vandezande K., Laenen I., Boon T., Van L. J., Vandenheede J., Moechars D., Loos R., Van L. F. 2000. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. The journal of biological chemistry 275: 41340-41349.
Srikanth V., Westcott B., Forbes J., Phan T. G., Beare R., Venn A., Pearson S., Greenaway T., Parameswaran V., Münch G. 2013. Methylglyoxal, cognitive function and cerebral atrophy in older people. The journals of gerontology: Series A 68: 68-73.
Stone W. L., Krishnan K., Campbell S. E., Qui M., Whaley S. G., Yang H. 2004. Tocopherols and the treatment of colon cancer. Annals of the New York academy of sciences 1031: 223-233.
Strachan M. W., Reynolds R. M., Marioni R. E. 2011. Cognitive function, dementia and type 2 diabetes mellitus in the elderly Nature reviews. Endocrinology 7: 108-114.
Suarna C., Hood R. L., Dean R. T., Stocker R. 1993. Comparative antioxidant activity of tocotrienols and other natural lipid-soluble antioxidants in a homogeneous system, and in rat and human lipoproteins. Biochimica et Biophysica Acta (BBA) - lipids and lipid metabolism 1166: 163-170.
Sylvester P. W and Shah S. 2005. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells. Asia Pacific journal of clinical nutrition 14: 366-373.
Sylvester P. W., Shah S. J. 2005. Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. Front bioscience 10: 699-709.
Tan B. 1989. Palm carotenoids, tocopherols and tocotrienols. Journal of American oil chemists' society 66: 770-777.
Theriault A., Chao J. T., Wang Q., Gapor A., Adeli K. 1999. Tocotrienol: a review of its therapeutic potential. Clinical biochemistry 32: 309-319.
Thornalley P. J. 2005. Dicarbonyl intermediates in the Maillard reaction. Annals of the New York Academy of sciences 1043: 111-117.
Thornalley PJ. 1996. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification—a role in pathogenesis and antiproliferative chemotherapy. General pharmacology 27: 565-573.
Tomeo A. C., Geller M., Watkins T. R., Gapor A., Bierenbaum M. L. 1995. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids 30: 1179-1183.
Tóth A. E., Walter F. R., Bocsik A., Sántha P., Veszelka S., Nagy L., Puskás L. G., Couraud P. O., Takata F., Dohgu S., Kataoka Y., Deli M. A. 2014. Edaravone protects against methylglyoxal-induced barrier damage in human brain endothelial cells. PLoS One 9: e100152.
Traber M.G. 2007. Vitamin E regulatory mechanisms. Annual review of nutrition 27: 347-362.
Traber M.G., Burton G.W., Hughes L., Ingold K.U., Hidaka H., Malloy M., Kane J., Hyams J., Kayden H. J. 1992. Discrimination between forms of vitamin E by humans with and without genetic abnormalities of lipoprotein metabolism. Journal of lipid research 33: 1172-1182.
Traber M.G., Burton G.W., Ingold K.U., Kayden H.J. 1990. RRR- and SRR-alpha-tocopherols are secreted without discrimination in human chylomicrons, but RRR-alpha-tocopherol is preferentially secreted in very low density lipoproteins. Journal of lipid research 31: 675-685.
Vitek M. P., Bhattacharya K., Glendening J. M., Stopa E., Vlassara H., Bucala R. 1994. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proceedings of the national academy of sciences of the United States of America 91: 4766-4770.
Wada S., Satomi Y., Murakoshi M., Noguchi N., Yoshikawa T., Nishino H. 2005. Tumor suppressive effects of tocotrienol in vivo and in vitro. Cancer letters 229: 181-191.
Wang B., Aw T. Y., Stokes K. Y. 2018. N-acetylcysteine attenuates systemic platelet activation and cerebral vessel thrombosis in diabetes. Redox biology 14: 218-228.
Wang X., Chang T., Jiang B., Desai K., Wu L. 2007. Attenuation of hypertension development by aminoguanidine in spontaneously hypertensive rats: Role of methylglyoxal. American journal of hypertension 20: 629-636.
Wargovich M. J., Woods C., Hollis D. M., Zander M. E. 2001. Herbals, cancer prevention and health. The journal of nutrition 131: 3034-3036.
Xu Q., Park Y., Huang X. 2011. Diabetes and risk of Parkinson’s disease. Diabetes care 34: 910-915.
Yamada K., Nabeshima T. 2003. Brain-derived neurotrophic factor/TrkB signaling in memory processes. Journal of pharmacological sciences 91: 267-270.
Yang Y., Zhang J., Ma D., Zhang M., Hu S., Shao S., Gong C. X. 2013. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. Journal of Alzheimer’s disease 37: 637-648.
Yu W., Simmons-Menchaca M., Gapor A., Sanders B. G., Kline K. 1999. Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. Nutrition and cancer 33: 26-32.